To compare the progression-free survival time (PFS) in patients treated with 5-FU modulated
with CoFactor (plus bevacizumab) to 5-FU modulated with leucovorin (plus bevacizumab) in
patients with Metastatic Colorectal Cancer.
Inclusion Criteria:
1. Greater or equal to 18 years of age.
2. Surgically incurable, metastatic disease from proven colon or rectal adenocarcinoma.
3. Life expectancy of at least 3 months.
4. Histologically confirmed metastatic disease. Histological confirmation may be waived
if needle biopsy presents a significant risk to the subject and the clinical setting
is clinically consistent with metastasis of colorectal cancer, e. g. surgical findings
at laparotomy, or positive PET scan, synchronous histologically confirmed primary
tumor with typical metastatic pattern (stage D disease). Waiver can only be granted by
the Sponsor, and these cases will be kept to less than 10% of the total study
population.
5. Measurable disease. At least one unidimensionally measurable lesion with a diameter
≥10 mm using spiral CT scans (use of spiral CT must be documented in medical records
and used consistently throughout the study) or ≥20 mm using conventional CT or MRI
scans.
6. No prior systemic chemotherapy or immunotherapy for metastatic or advanced local
disease. However patients may have had radiosensitizing doses of fluoropyrimidines
(only 5-FU or capecitabine, with or without leucovorin or levamisole is permitted) if
completed 6 months prior to treatment on this protocol. No prior irinotecan or
oxaliplatin in combination with radiotherapy is allowed.
7. Prior adjuvant therapy is allowed if completed more than 6 months prior to treatment
on this protocol. Regimens which included oxaliplatin and irinotecan are allowed.
8. ECOG Performance Status is 0-2 or Karnofsky performance level of 100-70.
9. Willing and able to provide written informed consent.
Exclusion Criteria:
1. Any prior exposure to bevacizumab.
2. A known intolerance to fluoropyrimidine (5-FU, capecitabine, floxuridine, UFT) therapy
suggestive of dihydropyrimidine dehydrogenase (DPD) deficiency.
3. Use of the following drugs are not permitted on the protocol: sorivudine (or other
nucleoside analogue), or Brivudin™ (or other DPD inhibitor).
4. Pregnancy or lactation. Women with a positive (or no) serum or urine pregnancy test
within 15 days of Cycle 1 Week 1. Women must have been amenorrheic for at least 12
consecutive months to be considered to lack potential for child bearing.
5. If sexually active and of child-bearing potential, failure to agree to use adequate
contraception during this study and for 60 days after discontinuation of study
medication.
6. A concurrent infection, including diagnoses of FUO and evidence of possible central
line sepsis (subjects must be afebrile at the start of therapy).
7. Any unstable oncologic emergency syndromes: superior vena cava syndrome, rising
bilirubin needing stent placement, spinal cord compression, active bleeding, etc.
8. History of CNS metastasis, or other brain tumor, or history of stroke.
9. Radiation therapy within 6 weeks of Cycle 1 Week 1, or any radiation therapy which
encompasses target lesions selected for this study unless those lesions have
documented progression of disease.
10. Major surgery, open biopsy, or significant traumatic injury within 4 weeks of Cycle 1
Week 1, or anticipated need for major surgical procedure during the course of the
study.
11. Fine needle aspiration or placement of a central line catheter within 7 days of Cycle
1 Week 1.
12. Inadequate bone marrow, liver or kidney function defined as:
- Serum creatinine more than 1. 5 times the upper limit of normal,
- Urine protein to creatinine ratio >1,
- Serum bilirubin > 2 times the upper limit of normal,
- ANC < 1. 5 x 109/L,
- Hemoglobin < 9. 0 g / dL
- Platelet count < 90 x 109/L,
- SGOT (AST) and SGPT (ALT) more than 3 times the upper limit of normal, or more
than 5 times the upper limit of normal for subjects with documented liver
metastases.
13. Myocardial infarction, transient ischemic attack, cerebral bleeding, translumenal
cardiac angiography or cardiac stent placement or other arterial thrombotic event
within 12 months prior to Cycle 1 Week 1.
14. Active, clinically significant cardiovascular or symptomatic arterial peripheral
vascular disease [e. g., uncontrolled hypertension, congestive heart failure,
claudication, unstable angina, symptomatic cardiac arrhythmia, or New York Heart
Association (NYHA) Class 2 or greater].
15. Presence of serious non-healing wounds, gastro-duodenal ulcers active by endoscopy,
gastro-intestinal perforation or intra-abdominal abscess, skin ulcers, or bone
fractures.
16. INR >1. 5 unless on therapeutic doses of oral anticoagulants (e. g. warfarin). If so,
must have an in-range INR (usually between 2-3) on a stable dose of drug.
17. Participation in another experimental drug study within 4 weeks prior to Cycle 1 Week
1.
18. Known or suspected anaphylaxis reaction to leucovorin or any allergic reaction to a
drug which, in the opinion of the Investigator, suggests an increased potential for a
hypersensitivity to CoFactor or other study drug including excipients.
19. Presence of organ allograft requiring immunosuppressive therapy.
20. Unwilling or unable to comply with the study protocol or history of psychiatric
disability judged by the investigator to preclude granting of informed consent.
Research Center In, Zrenjanin, Serbia and Montenegro
Research Center In, Florence, Alabama, United States
Mercy General Hospital, Sacramento, California 95819, United States
Research Center In, San Diego, California, United States
Research Center In, Sacramento, California, United States
Research Center In, Poway, California, United States
Research Site In, San Diego, California, United States
Research Center In, Apple Valley, California, United States
Research Center In, Rancho Mirage, California, United States
Research Center In, Vista, California, United States
Research Center In, Beverly Hills, California, United States
Research Center In, Anaheim, California, United States
Research Center In, Irvine, California, United States
Research Center In, Mission Hills, California, United States
Research Center In, Port St. Lucie, Florida, United States
Research Center In, Merritt Island, Florida, United States
Research Center In, Boynton Beach, Florida, United States
Research Center In, Tarpon Springs, Florida, United States
Research Center In, Skokie, Illinois, United States
Research Center In, Gurnee, Illinois, United States
Research Center In, Joliet, Illinois, United States
Research Center In, Indianapolis, Indiana, United States
Research Center In, Wichita, Kansas, United States
Research Center In, Hazard, Kentucky, United States
Research Center In, Baltimore, Maryland, United States
Research Center In, Grand Rapids, Michigan, United States
Research Center In, Flint, Michigan, United States
Research Center In, Port Huron, Michigan, United States
Research Center In, Freesoil, Michigan, United States
Research Center In, Jackson, Mississippi, United States
Research Center In, Las Vegas, Nevada, United States
Research Center In, Reno, Nevada, United States
Research Center In, Henderson, Nevada, United States
Research Center In, Cherry Hill, New Jersey, United States
Research Center In, Farmington, New Mexico, United States
Research Center In, East Setauket, New York, United States
Research Center In, Greenville, North Carolina, United States
Research Center In, Middletown, Ohio, United States
Research Center In, Cranston, Rhode Island, United States
Research Center In, Charleston, South Carolina, United States
Research Center In, Columbia, South Carolina, United States
Research Center In, Collierville, Tennessee, United States
Research Center In, Chattanooga, Tennessee, United States
Research Center In, Fort Worth, Texas, United States
Research Center In, Ogden, Utah, United States
Research Center In, Walla Walla, Washington, United States
Research Center In, Lacey, Washington, United States
